Background: Paclitaxel is currently only available as an intravenous (i.v.) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to i.v. paclitaxel as a secondline therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure.
Introduction
Paclitaxel is widely used as a second-line treatment in patients with gastric cancer, based on evidence from phase II and III trials that established its role when given weekly or 3 weekly in previously treated patients [1, 2] . Despite its widespread use, paclitaxel is currently only available as an intravenous (i.v.) formulation due to its poor solubility in water. Consequently, paclitaxel is generally given with Cremophor EL (BASF Corp, Ludwigshafen, Germany) as a vehicle to aid i.v. administration [3] [4] [5] [6] , although its use is associated with hypersensitivity reactions [7] and altered/non-linear pharmacokinetics of paclitaxel [8, 9] . The oral administration route is preferred to the i.v. route for paclitaxel, not only for convenience but also because achieving a longer exposure is more important than a higher concentration for the efficacy of cell-cycle phase-specific agents such as paclitaxel. Attempts to develop an oral formulation of paclitaxel have met with limited success because of the need for a concomitant orally administered P-glycoprotein inhibitor, e.g. cyclosporin A [10, 11] , which can potentially interact with other medications including substrates for P-glycoprotein and/or cytochrome P450 3A [12] . DHP107 (Daehwa Pharmaceutical Co., Ltd, Seoul, Korea) is a novel oral formulation composed of lipid ingredients and paclitaxel, which is systemically absorbed without the need for P-glycoprotein inhibitors or Cremophor EL [13] . DHP107 has been shown to be safe and feasible in patients with advanced malignancies refractory to all standard treatments [14, 15] . In a phase I/IIa study of DHP107 in patients with advanced gastric cancer (AGC) or metastatic solid tumors, the recommended dose of DHP107 given in a weekly schedule was 200 mg/m 2 twice daily on days 1, 8, and 15 of a 4-week cycle [16] . This study also demonstrated promising efficacy for DHP107 in gastric cancer.
In light of this background evidence, the DREAM (DHP107 Randomized Evaluation in Adenocarcinoma of Metastatic gastric cancer) study (ClinicalTrials.gov: NCT01839773) was designed to evaluate if weekly oral DHP107 can substitute for 3-weekly i.v. paclitaxel in patients with AGC after failure of first-line therapy.
Materials and methods

Study design
The DREAM study was a multicenter, open-label, prospective, randomized phase III study to assess non-inferiority of oral DHP107 versus i.v. paclitaxel in patients with unresectable recurrent/AGC after failure of first-line therapy.
Patients were eligible for study entry if they were aged !20 years, had histologically or cytologically confirmed unresectable, recurrent, or metastatic gastric cancer, and had failed to respond to first-line chemotherapy with a fluoropyrimidine alone or a fluoropyrimidine plus platinum for metastatic or recurrent disease (adjuvant chemotherapy was considered as first-line chemotherapy if recurrence occurred within 6 months of its completion). All eligible patients had adequate bone marrow, liver, and renal function; an Eastern Cooperative Oncology Group performance status (ECOG PS) 2; life expectancy !3 months; and a measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) [17] .
The study protocol was approved by the Institutional Review Board of all participating sites. Written informed consent was obtained from all patients before enrollment.
Treatment
Based on data from a previous phase I/IIa trial [16] , eligible patients were randomized 1 : 1 to DHP107 (200 mg/m 2 twice daily orally on days 1, 8, and 15 every 4 weeks) or i.v. paclitaxel (175 mg/m 2 infused on day 1 every 3 weeks). DHP107 was taken without premedication after breakfast and after supper (within 1 h of each meal), to give an interval between doses of 10 h. Each patient's dose was calculated from their body surface area (calculated using Mosteller's formula) on day 1 of every cycle and rounded to the nearest 50 mg (5 mL) as the minimum package unit is 5 mL (supplementary Table S1 , available at Annals of Oncology online). Patients were allowed to drink one cup of water ($200 mL) during the 30 min after oral administration. Paclitaxel was administered by i.v. infusion for 3 h after premedication (including dexamethasone, diphenhydramine, and H 2 -blocker).
If a patient had a severe adverse event (AE; grade 3/4), treatment doses were adjusted at the next administration (see supplementary Table S1 , available at Annals of Oncology online, for DHP107 and supplementary Table S2 , available at Annals of Oncology online, for i.v. paclitaxel).
Patients in the DHP107 arm visited the clinic for complete blood count (CBC) checks on days 1, 8, and 15 during the first cycle of treatment; if there were no withdrawals or dose modifications during the first cycle they were allowed to skip their scheduled clinic visits on days 8 and 15 during subsequent cycles (i.e. clinic visits on day 1 every cycle from thereon). Patients in the paclitaxel arm also visited the clinic for CBC checks on days 1, 8, and 15 during the first cycle, before reverting to clinic visits on day 1 of each cycle (i.e. once every 3 weeks).
Efficacy and safety outcomes
The primary end point was non-inferiority of progression-free survival (PFS) between the two treatment arms in the per-protocol population. Secondary end points included: overall response rate (ORR), overall survival (OS), and safety. Tumor measurements were taken via computed tomography at screening and every 6 weeks (61 week) from the randomization date; tumor response and disease progression were evaluated according to RECIST (version 1.1). PFS was measured from the date of randomization to disease progression or death from any cause, whichever occurred first. OS was defined as the time from randomization to the time of death from any cause. The Kaplan-Meier method was used for both PFS and OS.
AEs were classified using the Medical Dictionary for Regulatory Activities, and the number and percentage of patients who reported treatment-emergent AEs were summarized. AEs and laboratory test results (hematology and blood chemistry) were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).
Statistical analysis
Randomization was carried out using three stratification factors: (i) ECOG PS (0/1 versus 2); (ii) disease status [initially metastatic (patient presented with distant metastases) versus resected metastatic (patient presented with distant metastases with resection of primary tumor) or recurrent (patient presented with localized disease that recurred after curative resection)]; (iii) previous first-line chemotherapy (fluoropyrimidine versus fluoropyrimidine and platinum). With a power of 80% and one-sided type I error rate of 2.5%, a total of 204 events were required to observe non-inferiority of oral DHP107 versus i.v. paclitaxel with a noninferiority margin of 1.48 using the confidence interval (CI) approach. Allowing for a 10% drop-out rate, the target enrollment was 238 patients. For the efficacy analysis, sequential tests for non-inferiority were carried out, first with a non-inferiority margin of 1.48, then with a margin of 1.25. Definitions of the analysis sets used in the DREAM study protocol are provided in the supplementary Appendix, available at Annals of Oncology online .
Results
Between April 2013 and February 2015, a total of 238 patients with measurable disease (n ¼ 119 in each arm) were randomized to receive oral DHP107 or i.v. paclitaxel (Figure 1 ). This group of 236 patients comprised the full analysis set. Baseline patient and disease characteristics were well balanced between the arms (Table 1) . Details on previous therapies received by the full analysis set are shown in supplementary Table S3 , available at Annals of Oncology online.
Efficacy
The hazard ratio (HR) analyzed by Cox regression was 0.85 (95% CI 0.64-1.13) for DHP107 versus paclitaxel for the primary end point (PFS in the per-protocol population). The upper CI margin (1.13) was within the non-inferiority margin of 1.25. Median PFS (per protocol, investigators' evaluation) was 3.0 months (95% CI 1.7-4.0 months) for DHP107 and 2.6 months (1.8-2.8 months) for paclitaxel ( Figure 2A ). Median PFS in the full analysis set was almost identical to the per-protocol population (supplementary Figure S1 , available at Annals of Oncology online). A sensitivity analysis on PFS using independent central review showed similar results (HR ¼ 0.93; 95% CI 0.70-1.24; supplementary Figure S2 , available at Annals of Oncology online). In a planned subgroup analysis for PFS in the per-protocol population (supplementary Figure S3 , available at Annals of Oncology online), the majority of subgroups favored DHP107 over paclitaxel, further supporting the primary end point of non-inferiority.
Median OS in the full analysis set set was 9.7 months (95% CI 7.1-11.5 months) for DHP107 versus 8.9 months (95% CI Figure 2B ).
The ORR was 17.8% for DHP107 versus 25.4% for paclitaxel (P ¼ 0.155; Table 2 ) in the full analysis set. The disease-control rate was similar between arms (DHP107 54.4% versus paclitaxel 59.3%; P ¼ 0.358). Independent central review gave similar results for ORR (18.6% versus 16.9%) and disease-control rate (54.2% versus 59.3%) in the DHP107 and paclitaxel arms, respectively.
Safety
As expected, almost all patients experienced AEs during the study (DHP107 97.5%; paclitaxel 98.7%). A slightly lower proportion of patients had AEs that were considered to be related to DHP107 (89.8%) than paclitaxel (94.5%). Table 3 shows the most common clinical and hematological AEs reported during the study. Nausea, vomiting, diarrhea, and mucositis were more common with DHP107; peripheral sensory neuropathy was more common with paclitaxel.
There was no difference between treatment groups in terms of the number of serious AEs, which were observed in 46 DHP107-treated patients (39%) and 49 paclitaxel-treated patients (41%). Grade 3/4 AEs were reported in 68.6% versus 83.9% of DHP107-and paclitaxel-treated patients, respectively. The most common grade 3/4 AE was neutropenia (DHP107 42% versus paclitaxel 53%); febrile neutropenia was rare (DHP107 5.9% versus paclitaxel 2.5%). There were no hypersensitivity reactions with DHP107 even though patients received no premedication. In contrast, 2.5% of patients experienced hypersensitivity reactions with i.v. paclitaxel, despite receiving routine premedication. No treatment-related deaths were reported. Original article Annals of Oncology 
Discussion
The multicenter, open-label, prospective, randomized phase III DREAM study of oral DHP107 versus i.v. paclitaxel in patients with AGC after failure of first-line therapy met its primary end point. Oral DHP107 was non-inferior to i.v. paclitaxel in terms of PFS when given as a second-line treatment of patients with AGC. Oral DHP107 was also comparable to i.v. paclitaxel for other efficacy parameters (ORR, disease-control rate, OS). Cox regression analysis gave an HR of 0.86 (i.e. favoring DHP107), although there was no statistically significant difference between the groups. Also, the upper limit of the 95% CI for the HR in the DHP107 group was 1.13, which was lower than the final noninferiority margin of 1.25. The sensitivity analysis by independent central review confirmed the non-inferiority of DHP107 versus i.v. paclitaxel. Therefore, non-inferiority of DHP107 versus i.v. paclitaxel was demonstrated.
The efficacy findings reported for oral DHP107 versus i.v. paclitaxel in DREAM are in line with previous studies of standard doses of weekly i.v. paclitaxel, in which response rates of 16%-24% and median PFS of 2.1-2.6 months were reported [2, [18] [19] [20] . The findings are also similar to those from a Japanese study of 3-weekly paclitaxel in a mixed population of patients with AGC (with previously treated and untreated metastatic disease) in which the response rate was 28% and median OS was 7.7 months [1] . Our findings also compare well with those from a randomized phase III trial of irinotecan versus paclitaxel every 4 weeks after failure of prior fluoropyrimidine/platinum-based therapy [2] . In their analysis, Hironaka et al. reported a median PFS of 3.6 months, median OS of 9.5 months, and an ORR of 20.9% with second-line paclitaxel treatment [2] . Taken together, our findings stand up to comparison with these previously reported trials and indicate non-inferiority of weekly oral DHP107 compared with 3-weekly i.v. paclitaxel.
Oral DHP107 and i.v. paclitaxel were well tolerated, with no significant differences in AE profiles. Nausea, vomiting, diarrhea, and mucositis were more common with DHP107 than with i.v. paclitaxel, which might be related to a direct effect on the gastrointestinal mucosa of the paclitaxel in DHP107. These findings reflect the general AE profile of each drug as reported previously [7-9, 14, 16] . The decreased occurrence of peripheral sensory neuropathy with DHP107 perhaps indicates that DHP107 has less neurological toxicity than i.v. paclitaxel. This could be explained, at least in part, by avoiding additional neurotoxicity associated with the use of Cremophor EL (which is used to aid i.v. administration of paclitaxel) [21] , and may have an appreciable positive impact on quality of life and disease burden for patients during their cancer journey. This is particularly important given that neurotoxicity is a common and troublesome AE associated with platinum agents used in the first-line treatment setting. Patients progressing and receiving further chemotherapy generally have some residual neurotoxicity, which could be exacerbated by giving another potentially neurotoxic agent as second-line therapy. The fact that DHP107 is an oral agent may also be preferable to i.v. paclitaxel, given the well-known preference of patients with cancer for oral compared with i.v. therapies [22] . The rate of grade 3/4 AEs was identical in both treatment arms, the most common being neutropenia. This again was expected based on previously reported data. Importantly, serious AEs were comparable between the two arms. There were no hypersensitivity reactions with DHP107, although some were seen with paclitaxel, despite premedication. This is an important feature of DHP107, given that i.v. paclitaxel is generally given with Cremophor EL, which is associated with hypersensitivity reactions [7] and affects paclitaxel pharmacokinetics [8, 9] .
Paclitaxel is a cell cycle-specific agent similar to 5-fluorouracil, and in vitro studies have shown that prolonged exposure is more important than higher peak concentration for its anticancer cytotoxicity [23] . However, this advantage of prolonged exposure in efficacy was not established for paclitaxel in clinical trials. Several clinical trials have compared short (3 h) versus long (24 or 96 h) infusions of paclitaxel and, although some reported significantly higher activity [24] , a meta-analysis showed that prolonged infusion was associated with decreased neurotoxicity but without any improvement in efficacy [25] . Furthermore, as paclitaxel is available only as an i.v. formulation, prolonged administration is more inconvenient and has therefore not been pursued. The availability of an oral formulation of paclitaxel (DHP107) may allow exploration of whether administration of paclitaxel as an extended regimen might be advantageous in terms of efficacy and safety.
In terms of study limitations, we acknowledge that the noninferiority margin set in the trial might be considered relatively easy to attain, although this relaxed margin has been used and accepted by authorities including EMA. A stricter inferiority margin might be preferable, but this would have necessitated the inclusion of more patients. We also acknowledge that we compared the weekly regimen of DHP107 with a 3-weekly (not weekly) regimen of paclitaxel. The main reason for this is that 3-weekly paclitaxel is the only currently approved schedule of paclitaxel in Korea and, although the weekly regimen is widely used, it has not been shown to be equivalent or superior to 3-weekly paclitaxel in gastric cancer. Finally, we acknowledge that there are currently no data available on DHP107 in Caucasian patients.
In conclusion, DHP107 was a tolerable and feasible treatment for patients with AGC after failure of first-line therapy, with efficacy comparable to i.v. paclitaxel. DHP107 is the first oral paclitaxel formulation to demonstrate equivalent efficacy and safety to i.v. paclitaxel for the treatment of AGC. This novel oral formulation of paclitaxel may also prove useful in other tumor types where i.v. paclitaxel is currently used (e.g. breast cancer).
